Reata Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. Warren Huff
- Full Time Employees
- 321
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5320 Legacy Drive Plano TX United States of America 75024
- IPO Date
- May 26, 2016
- CIK
- 0001358762
- Website
- reatapharma.com
- Similar Companies
- Business
- Reata Pharmaceuticals, Inc. (RETA), a biopharmaceutical company founded in 2002 and headquartered in Plano, Texas, focuses on the discovery, development and commercialization of novel oral antioxidative and anti-inflammatory small-molecule therapies that activate the Nrf2 pathway and inhibit NF-kB for severe life-threatening diseases with limited treatment options; primary products include SKYCLARYS (omaveloxolone), the first FDA-approved therapy in 2023 for Friedreich's ataxia in patients aged 16 and older, with subsequent approvals in the European Union, Canada, the United Kingdom and Brazil in April 2025, and bardoxolone methyl under investigation in Phase 2/3 trials for chronic kidney disease including Alport syndrome, diabetic CKD, IgA nephropathy and autosomal dominant polycystic kidney disease, as well as pulmonary arterial hypertension associated with connective tissue disease; the pipeline also encompasses earlier-stage candidates such as RTA 901 for neurological diseases and RTA 1701 for autoimmune, inflammatory and fibrotic conditions. The company operates primarily in the United States with global reach through partnerships, targeting rare neuromuscular, renal, cardiovascular and metabolic disorders in patients lacking approved therapies. Reata maintains licensing and collaboration agreements with Kyowa Kirin for bardoxolone methyl in renal and related indications across Japan, China, South Korea and select Southeast Asian markets, and with AbbVie for bardoxolone and second-generation Nrf2 activators outside the U.S. excluding those Asian territories. In a transformative development completed on September 26, 2023, Reata was acquired by Biogen Inc. for approximately $6.5-7.3 billion, resulting in its delisting from Nasdaq, integration into Biogen's rare disease portfolio and redirection of its operations and website to Biogen's platform, with no material updates to products or pipeline reported since the acquisition through 2025.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
The 7 Most Promising Momentum Stocks to Own Now
The 3 Most Promising Pharma Stocks to Own Now
REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA